Assembly Biosciences Company Profile (NASDAQ:ASMB)

About Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences logoAssembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:ASMB
  • CUSIP: 92282210
  • Web:
  • Market Cap: $581.71 million
  • Outstanding Shares: 17,364,000
Average Prices:
  • 50 Day Moving Avg: $31.28
  • 200 Day Moving Avg: $25.26
  • 52 Week Range: $10.93 - $36.31
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.17
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $3.04 million
  • Price / Sales: 182.89
  • Book Value: $3.26 per share
  • Price / Book: 9.82
  • EBITDA: ($50,920,000.00)
  • Return on Equity: -68.84%
  • Return on Assets: -43.64%
  • Current Ratio: 6.48%
  • Quick Ratio: 6.48%
  • Average Volume: 65,217 shs.
  • Beta: 0.83
  • Short Ratio: 6.37

Frequently Asked Questions for Assembly Biosciences (NASDAQ:ASMB)

What is Assembly Biosciences' stock symbol?

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences, Inc. (NASDAQ:ASMB) released its quarterly earnings results on Monday, November, 17th. The company reported ($1.33) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.84. View Assembly Biosciences' Earnings History.

Where is Assembly Biosciences' stock going? Where will Assembly Biosciences' stock price be in 2017?

1 brokers have issued 1 year price targets for Assembly Biosciences' shares. Their forecasts range from $35.00 to $35.00. On average, they anticipate Assembly Biosciences' stock price to reach $35.00 in the next twelve months. View Analyst Ratings for Assembly Biosciences.

Who are some of Assembly Biosciences' key competitors?

Who are Assembly Biosciences' key executives?

Assembly Biosciences' management team includes the folowing people:

  • Derek A. Small, President, Chief Executive Officer, Director
  • David J. Barrett CPA,, Chief Financial Officer, Chief Operating Officer
  • Uri Lopatin M.D., Vice President - Research & Development, Chief Medical Officer
  • William R. Ringo, Independent Non-Executive Chairman of the Board
  • Alan James Lewis Ph.D., Director
  • Anthony E. Altig, Independent Director
  • Mark Auerbach CPA,, Independent Director
  • Richard DiMarchi, Independent Director

How do I buy Assembly Biosciences stock?

Shares of Assembly Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Assembly Biosciences' stock price today?

One share of Assembly Biosciences stock can currently be purchased for approximately $32.02.

MarketBeat Community Rating for Assembly Biosciences (NASDAQ ASMB)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  85 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  153
MarketBeat's community ratings are surveys of what our community members think about Assembly Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Assembly Biosciences (NASDAQ:ASMB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $35.00 (9.31% upside)
Consensus Price Target History for Assembly Biosciences (NASDAQ:ASMB)
Price Target History for Assembly Biosciences (NASDAQ:ASMB)
Analysts' Ratings History for Assembly Biosciences (NASDAQ:ASMB)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/17/2017Chardan CapitalReiterated RatingBuyMediumView Rating Details
8/19/2016William BlairInitiated CoverageMarket Perform -> OutperformN/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for Assembly Biosciences (NASDAQ:ASMB)
Earnings by Quarter for Assembly Biosciences (NASDAQ:ASMB)
Earnings History by Quarter for Assembly Biosciences (NASDAQ ASMB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/17/2014Q3 2014($0.49)($1.33)ViewN/AView Earnings Details
4/2/2014($0.28)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Assembly Biosciences (NASDAQ:ASMB)
2017 EPS Consensus Estimate: ($2.63)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.03)($0.03)($0.03)
Q2 20171($0.79)($0.79)($0.79)
Q3 20171($0.88)($0.88)($0.88)
Q4 20171($0.93)($0.93)($0.93)
(Data provided by Zacks Investment Research)


Dividend History for Assembly Biosciences (NASDAQ:ASMB)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Assembly Biosciences (NASDAQ:ASMB)
Insider Ownership Percentage: 19.60%
Institutional Ownership Percentage: 72.27%
Insider Trades by Quarter for Assembly Biosciences (NASDAQ:ASMB)
Institutional Ownership by Quarter for Assembly Biosciences (NASDAQ:ASMB)
Insider Trades by Quarter for Assembly Biosciences (NASDAQ:ASMB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/11/2016Derek A. SmallCEOBuy10,000$5.53$55,300.00View SEC Filing  
5/27/2014Russell H EllisonCEOBuy13,000$0.92$11,960.00View SEC Filing  
5/23/2014David Jonathan BarrettCFOBuy6,980$0.86$6,002.80View SEC Filing  
5/23/2014Russell H EllisonCEOBuy20,000$0.91$18,200.00View SEC Filing  
5/21/2014Russell EllisonCEOBuy10,000$0.87$8,700.00View SEC Filing  
5/20/2014David Jonathan BarrettCFOBuy40,000$0.88$35,200.00View SEC Filing  
2/5/2013Russell H EllisonCEOBuy15,000$2.55$38,250.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Assembly Biosciences (NASDAQ:ASMB)
Latest Headlines for Assembly Biosciences (NASDAQ:ASMB)
DateHeadline logoCommit To Purchase Assembly Biosciences At $25, Earn 15.7% Annualized Using Options - October 13 at 9:12 PM logoCheck-Cap (CHEK) & Assembly Biosciences (ASMB) Head-To-Head Comparison - October 12 at 2:26 AM logoAssembly Biosciences, Inc. (ASMB) Upgraded by Zacks Investment Research to Hold - October 10 at 5:46 PM logoReviewing Assembly Biosciences (ASMB) & Its Competitors - October 4 at 2:10 AM logoAssembly Biosciences Selects Next-Generation CpAM Candidate for Advancement into Clinical Development - October 2 at 3:59 PM logoAssembly Biosciences Announces 2017 AASLD Presentations - October 2 at 3:59 PM logoAnalyzing Assembly Biosciences (ASMB) and Its Competitors - October 1 at 4:38 PM logoHead-To-Head Contrast: Assembly Biosciences (ASMB) & Its Peers - October 1 at 6:24 AM logoAssembly Biosciences (ASMB) Presents At Cambridge Healthtech Institute's 15th Annual Discovery On Target - Slideshow - September 28 at 4:33 PM logoAnalyzing Assembly Biosciences (ASMB) & Its Rivals - September 28 at 8:28 AM logoAssembly Biosciences Selects Next-Generation CpAM Candidate for Advancement into Clinical Development - GlobeNewswire (press release) - September 28 at 12:56 AM logoHead-To-Head Comparison: Assembly Biosciences (ASMB) and Its Rivals - September 27 at 4:32 PM logoAssembly Biosciences (ASMB) vs. Its Peers Critical Survey - September 26 at 2:08 PM logoContrasting Assembly Biosciences (ASMB) & The Competition - September 24 at 10:08 PM logoCritical Contrast: Assembly Biosciences (ASMB) vs. Its Rivals - September 20 at 8:08 AM logoAssembly Biosciences, Inc. (ASMB) Earns "Buy" Rating from Chardan Capital - September 20 at 6:26 AM logoContrasting Assembly Biosciences (ASMB) and Its Competitors - September 17 at 10:16 AM logoDARA Biosciences (DARA) & Assembly Biosciences (ASMB) Head to Head Review - September 16 at 12:24 PM logoContrasting Assembly Biosciences (ASMB) and Aimmune Therapeutics (AIMT) - September 4 at 4:28 AM logoContrasting Assembly Biosciences (ASMB) & Supernus Pharmaceuticals (SUPN) - August 21 at 10:26 AM logoAssembly Biosciences, Inc. – Value Analysis (NASDAQ:ASMB) : August 15, 2017 - August 15 at 10:08 PM logoAssembly Biosciences, Inc. (NASDAQ:ASMB) Forecasted to Earn Q3 2017 Earnings of ($0.88) Per Share - August 14 at 3:36 AM logoAnalyzing Rockwell Medical (RMTI) and Assembly Biosciences (NASDAQ:ASMB) - August 9 at 10:26 AM logoReviewing Assembly Biosciences (ASMB) & Supernus Pharmaceuticals (SUPN) - August 6 at 8:22 PM logoAssembly Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : ASMB-US : August 2, 2017 - August 2 at 4:54 PM logo Assembly Biosciences, Inc. (ASMB) Given Consensus Recommendation of "Strong Buy" by Analysts - August 2 at 7:18 AM logoAssembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - July 28 at 5:19 PM logoHead to Head Contrast: TherapeuticsMD (TXMD) vs. Assembly Biosciences (ASMB) - July 19 at 8:25 AM logoAssembly Biosciences (ASMB) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow - June 8 at 4:23 PM logoAssembly Biosciences (ASMB) Completes Dose Ranging Portion of Phase 1a/1b Trial of ABI-H0731 - February 17 at 6:29 PM logoASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - January 10 at 8:43 PM logo8:11 am Assembly Biosciences enters into research, development, collaboration and license agreement with Allergan (AGN); Allergan to make upfront payment of $50 mln - January 10 at 3:42 PM logoASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, - January 10 at 3:42 PM logoAllergan (AGN) Enters Licensing Agreement with Assembly Biosciences (ASMB) to Obtain Worldwide Rights to GI Programs - January 9 at 4:29 PM logoAGN Stock Is Preparing For Battle (AGN) - January 9 at 4:29 PM logoASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex - December 9 at 8:43 PM logoASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers - December 6 at 12:37 PM logoAssembly Biosciences (ASMB) Commences ABI-H0731 Phase 1 as HBV Treatment - November 10 at 2:05 PM logoAssembly Biosciences (ASMB) Worth a Look: Stock Up 7.3% - October 17 at 8:26 AM logoASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Other Events - September 2 at 8:19 AM logoASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a - June 6 at 4:02 PM logoASSEMBLY BIOSCIENCES, INC. Files SEC form 10-K, Annual Report - March 11 at 4:04 PM logoAssembly Biosciences to Webcast Upcoming Investor Conferences - GlobeNewswire (press release) - February 19 at 2:59 PM



Assembly Biosciences (ASMB) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.